Evidence Published in Diabetes Research and Clinical Practice Shows 10 kHz Therapy Yields Lasting Pain Relief and Enhances Health-Related Quality of Life and Sleep Published 24-month data from the ...
Nevro Corp. NVRO recently announced the publication of new 24-month data from the SENZA Nonsurgical Refractory Back Pain (NSRBP) multicenter randomized controlled trial (RCT) in the Journal of ...
Experts in diabetes, pain and health services from the Worldwide Initiative for Diabetes Education recommend spinal cord stimulation when symptoms aren't responsive to first- or second-line therapies ...
Nevro is a company dedicated to the design and manufacture of medical devices. I believe that further news about the efficacy of the product, sufficient marketing, and internationalization efforts ...
Nevro Corp. NVRO recently announced that it has received CE mark approval for the Senza Omnia Spinal Cord Stimulation (SCS) system. This is a next-generation SCS system, which has been created and ...
Nevro is bringing artificial intelligence to its spinal cord stimulation solutions. The Redwood City, CA-based company said it won FDA approval for the HFX iQ with HFX AdaptivAI - a responsive, ...
Nevro is looking at strategic options after citing heavy competition from larger players in the spinal cord stimulation market. The measure comes several months after Nevro announced it would cut ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results